Combining their expertise in clinical trials support and cellular therapies, BloodCenter of Wisconsin (BCW) and the San Diego Blood Bank (SDBB) have created a strategic partnership to accelerate advancements in research and patient care. Together, BloodCenter of Wisconsin and San Diego Blood Bank will offer Celluvative™ – a portfolio of products and clinical trial services that will include esoteric laboratory testing, blood products for research and manufacturing applications, cell processing, and access to a broad database of diverse donors who have expressed interest in clinical trials.
“Through the strength of our partnership, we are able to offer end-to-end services to academic organizations, research institutions and other industry partners who are working to develop novel cellular therapy approaches,” said Matthew Anderson, M.D., Ph.D., medical director, BloodCenter of Wisconsin Diagnostic Laboratories. “Among other offerings, our Celluvative portfolio enables access to an extremely diverse donor database – an invaluable resource to enable advances in the area of regenerative medicine and drug discovery.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7855451-bloodcenter-sdbb-celluvative/
TruTag Technologies, Inc., Honolulu-based innovator of an edible security platform to address the trillion dollar global counterfeit problem and the issue of food and medicine safety, has been named a 2014 Technology Pioneer by the World Economic Forum.
To view Multimedia News Release, go to http://www.multivu.com/mnr/63075-trutag-technologies-2014-technology-pioneer-by-world-economic-forum
CPhI Worldwide, part of UBM Live’s Pharmaceutical Portfolio, today celebrates its 25th birthday by releasing the first in a series of ‘made at CPhI’ pharma stories. These will follow 25 pharma industry successes that have directly resulted from meetings at CPhI. The first story charts Global Pharmaceutical Relief from a first meeting at CPhI only two years ago to today and providing hundreds of millions of dollars worth of medicines to the developing world via NGOs- not just another business story, but a great example of the CPhI family helping to proliferate healthcare throughout the globe.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/72762554-cphi-worldwide-celebrates-25-years/
Federally funded research that provides a deep understanding of cancer is spurring advances against many types of the disease. With a strong bipartisan commitment from Congress to keep investment in biomedical research a national priority, we can accelerate our pace of progress and save more lives from cancer, according to the seventh annual American Association for Cancer Research (AACR) Cancer Progress Report, released today.
Basic research in the fields of immunology and cancer genetics has recently been harnessed to develop two new forms of cancer treatment: immunotherapy and precision medicine. As detailed in the report, the utility of these treatments is expanding rapidly. In May 2017, the U.S. Food and Drug Administration (FDA) heralded a new dawn for precision medicine when it approved the immunotherapeutic pembrolizumab (Keytruda) for treating patients with any solid tumor harboring specific genetic characteristics. This is the first anticancer therapeutic approved based on cancer biomarkers rather than the location in the body where the cancer originated.
To view the multimedia release go to:
https://www.multivu.com/players/English/8155051-aacr-cancer-progress-report-2017/
Newron Pharmaceuticals S.p.A. (“Newron”), a research and development company focused on novel CNS and pain therapies, and its partner Zambon S.p.A., an international pharmaceutical company strongly committed to the CNS therapeutic area, announced today that the EU Committee for Medicinal Pro-ducts for Human Use (CHMP) recommended that the European Commission approve the use of Xadago™ (safinamide) as add-on to L-dopa alone or in combination with dopamine agonists, entacapone, amantadine, and/or anticholinergics, for the treatment of patients with mid-late stage Parkinson’s disease experiencing motor fluctuations despite being stabilized on ‘Standard of Care’.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7406951-chmp-xadago-parkinsons/
New science in molecular and genetic testing for breast, colon, and prostate cancer, as well as leukemia, will be among the special features at the College of American Pathologists’ annual scientific and education meeting, CAP’14—THE Pathologists’ Meeting, Sept. 7-10 at the Hyatt Regency in Chicago.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7270051-college-of-american-pathologists-cap-14-what-s-next-in-cancer-testing/
Global biotherapeutics leader CSL Behring today announced that results were published in the New England Journal of Medicine (NEJM) from the COMPACT study, a pivotal Phase III study evaluating the safety and efficacy of CSL830 (a novel, investigational, self-administered, subcutaneous C1-Esterase Inhibitor [C1-INH] Human replacement therapy) for the prevention of HAE attacks. The study met its primary efficacy endpoint, significantly reducing the time-normalized number of HAE attacks. In addition, the study met its secondary endpoints, including the responder rate (patients who had at least a 50% reduction in their attack rate) and the number of rescue medication uses. If approved by the FDA, CSL830 would be the first and only subcutaneous preventative therapy for HAE.
To view the multimedia release go to:
https://www.multivu.com/players/English/8056151-csl-behring-subcutaneous-c1-esterase-inhibitor-hae-patients/
The foetus moves its mouth in an exaggerated manner when it hears a human voice. This occurs from the 16th week of pregnancy (with a foetus of 11cm) and only when the voice reaches it through an intravaginal device developed for this purpose. This is one of the conclusions of the study presented by Dr. Álex García-Faura, the Scientific Director of the Institut Marquès, at the 25th European Congress of Perinatal Medicine held in Maastricht (Netherlands).
The study finds that babies hear practically no external noise and only react when sound reaches them through the vagina, which confirms that they hardly hear voices through the mother’s abdomen. Their reactions were studied using Babypod®, a small device that is inserted into the vagina like a tampon and is connected to a mobile phone, enabling the voice of the mother or anyone else to reach the foetus.
To view the multimedia release go to:
http://www.multivu.com/players/uk/7859951-institut-marques-babies-react-mother-voice/
Today Safe Kids Worldwide released a new research report that found kids are getting into medicine at an alarming rate. Every minute of every day, a poison control center receives a call about a potential medicine poisoning for a child age five and under. And 67,000 times each year, or every eight minutes, a young child goes to the emergency room for medicine poisoning. This is a 30 percent increase over the past ten years.
In its report entitled An In-Depth Look at Keeping Young Children Safe Around Medicine, Safe Kids examines data from the U.S. Consumer Product Safety Commission, information from poison control centers and findings from several focus groups among moms. The report reviews what is happening in households that leads to these disturbing numbers and offers parents simple things they can do to protect their children.
To view Multimedia News Release, go to http://www.multivu.com/mnr/60845-safe-kids-worldwide-keeping-young-children-safe-around-medicine
The science of bionics helped the more than 1 million Americans with leg amputations take a giant step forward, as the Rehabilitation Institute of Chicago (RIC) revealed clinical applications for the world’s first thought-controlled bionic leg in this week’s New England Journal of Medicine. This innovative technology represents a significant milestone in the rapidly-growing field of bionics. Until now, only thought-controlled bionic arms were available to amputees.
To view Multimedia News Release, go to http://www.multivu.com/mnr/63339-rehabilitation-institute-of-chicago-first-thought-controlled-bionic-leg
Parents want to do the best for their children, especially when they’re not feeling well. That often means giving liquid, over-the-counter (OTC) medications when they have a cold, fever or the flu. But even the best intentions can go wrong when it comes to dosing children’s OTC medicines.
OTC cough and cold medicines are safe and effective when used as directed – this includes always giving your child the precise, recommended dose. When it’s late at night and your child is sick, it may seem easier to reach for whatever is nearby, like a kitchen spoon, instead of taking the time to find the right dosing cup or syringe that came with the medicine. While 63 percent of parents surveyed say they prefer milliliter dosing devices to measure their children’s liquid medicine, 8 out of 10 parents* have given the wrong dose of liquid medicine to their child by accident.
To view the multimedia release go to:
https://www.multivu.com/players/English/8171651-chpa-educational-foundation-know-your-otcs/
Northwestern Medicine’s Bluhm Cardiovascular Institute is celebrating the success of its transcatheter valve program, a pioneering technology that replaces or repairs leaky heart valves without open-heart surgery. On August 25, 2016, more than 50 former transcatheter valve replacement patients and their family members celebrated the life-saving procedure that has extended both their lives and their ability to enjoy them.
The Bluhm Cardiovascular Institute hit the milestone of being the first hospital in Illinois to perform the 500th TAVR, or transcatheter aortic valve replacement, since the program’s inception in 2008. Charles J. Davidson, MD, performed the 500th procedure on July 23, 2016.
To view the multimedia release go to:
http://www.multivu.com/players/English/7049452-northwestern-medicine-transcatheter-valve/
